Key points in patient support across hematological oncology
Felice Bombaci, from the AIL patient group for chronic myeloid leukemia (CML), Rome, Italy, discusses some important key topics in patient support in Italy for hematological malignancies. He speaks ab...
Author: VJHemOnc
Added: 08/10/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 10, 2018 Category: Cancer & Oncology Source Type: podcasts
Isatuximab: a next-generation monoclonal antibody
Speaking from the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, Paul Richardson, MD, of the Dana-Farber Cancer Institute, Boston, MA, tells us about isatu...
Author: VJHemOnc
Added: 08/07/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 7, 2018 Category: Cancer & Oncology Source Type: podcasts
Improving outcomes for R/R DLBCL with polatuzumab vedotin
Patients with relapsed, transplant ineligible diffuse large B-cell lymphoma (DLBCL) face extremely poor outcomes. In this video, recorded at the 23rd Congress of the European Hematology Association (E...
Author: VJHemOnc
Added: 08/07/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 7, 2018 Category: Cancer & Oncology Source Type: podcasts
Current and future therapies in mantle cell lymphoma
Speaking from the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, Simon Rule, MD, of Plymouth University, Plymouth, UK, discusses the current landscape of m...
Author: VJHemOnc
Added: 08/07/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 7, 2018 Category: Cancer & Oncology Source Type: podcasts
Response to MM therapy can vary based on a variety of factors
The response of patients with multiple myeloma (MM) to therapy is always variable. Speaking from the 23rd Congress of the European Hematological Association (EHA) 2018, held in Stockholm, Sweden, Shaj...
Author: VJHemOnc
Added: 08/07/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 7, 2018 Category: Cancer & Oncology Source Type: podcasts
MRD negativity as a treatment endpoint in CLL
Measurable residual disease (MRD) negativity is an important treatment endpoint for many hematological malignancies and has the potential to be used to inform therapy cessation decision making. Here, ...
Author: VJHemOnc
Added: 08/07/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 7, 2018 Category: Cancer & Oncology Source Type: podcasts
Integrating genomics into clinical hematology
The field of genomics is one of great promise, and there is hope that it can be implemented into all areas of medicine. Here, Willem Ouwehand, MD, PhD, of the University of Cambridge, Cambridge, UK ,s...
Author: VJHemOnc
Added: 08/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 6, 2018 Category: Cancer & Oncology Source Type: podcasts
Newly approved drugs for AML in the US
New drugs for acute myeloid leukemia (AML) are constantly being developed. In this video, recorded at the 23rd Congress of the European Hematological Association (EHA) 2018, held in Stockholm, Sweden,...
Author: VJHemOnc
Added: 07/31/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 31, 2018 Category: Cancer & Oncology Source Type: podcasts
Epigenetic therapies in AML: current and future landscape
Epigenetic therapies are constantly developing in the field of acute myeloid leukemia (AML). In this video, recorded at the 23rd Congress of the European Hematological Association (EHA) 2018, held in ...
Author: VJHemOnc
Added: 07/31/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 31, 2018 Category: Cancer & Oncology Source Type: podcasts
Developments in targeted AML therapies: venetoclax, quizartinib & amp; gilteritinib
Speaking from the 23rd Congress of the European Hematological Association (EHA) 2018 in Stockholm, Sweden, Naval Daver, MD, of the MD Anderson Cancer Center, Houston, TX, speaks about three new target...
Author: VJHemOnc
Added: 07/31/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 31, 2018 Category: Cancer & Oncology Source Type: podcasts
New technologies informing SOC in DLBCL
Chemotherapy is ineffective against a certain subset of diffuse large B-cell lymphoma (DLBCL) types. In this video, recorded at the 23rd Congress of the European Hematology Association (EHA) 2018, hel...
Author: VJHemOnc
Added: 07/31/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 31, 2018 Category: Cancer & Oncology Source Type: podcasts
CAVEAT: venetoclax and high dose chemo for elderly AML
Andrew Wei, MBBS, PhD, of Monash University, Melbourne, Australia, presented results from the CAVEAT trial (ACTRN12616000445471) at the 23rd Congress of the European Hematological Association (EHA) 20...
Author: VJHemOnc
Added: 07/31/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 31, 2018 Category: Cancer & Oncology Source Type: podcasts
CAR T-cells in hemonc: where do we stand?
CAR T-cells represent an important step forward in the treatment of a variety of hematological malignancies. At the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Stepha...
Author: VJHemOnc
Added: 07/30/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 30, 2018 Category: Cancer & Oncology Source Type: podcasts
Kinase inhibitor advances in MM: predictive biomarkers & amp; efficacy of daratumumab
Kinase inhibitors are one of the most successful forms of therapy for hematological malignancies, with further potential due to new advances. Speaking from the 1st European Myeloma Network Meeting (EM...
Author: VJHemOnc
Added: 07/26/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 26, 2018 Category: Cancer & Oncology Source Type: podcasts
How hematologists can improve care for patients with sickle cell disease
There are three times more patients with sickle cell disease (SCD) than cystic fibrosis (CF) in the USA, yet SCD receives 10 times less research funding than CF. In this interview, Sonia Wolf, MD, fro...
Author: VJHemOnc
Added: 07/24/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 24, 2018 Category: Cancer & Oncology Source Type: podcasts
